Technical Analysis for OCUL - Ocular Therapeutix, Inc.

Grade Last Price % Change Price Change
C 9.44 -0.21% -0.02
OCUL closed down 0.21 percent on Monday, March 18, 2024, on 79 percent of normal volume.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
20 DMA Resistance Bearish -0.21%
Pocket Pivot Bullish Swing Setup -0.21%
Volume Surge Other -0.21%
Wide Bands Range Expansion -0.21%
Fell Below 20 DMA Bearish 1.94%
Wide Bands Range Expansion 1.94%
1,2,3 Pullback Bullish Bullish Swing Setup -1.56%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.56%
Multiple of Ten Bearish Other -1.56%

   Recent Intraday Alerts

Alert Time
Up 1% about 16 hours ago
60 Minute Opening Range Breakout about 17 hours ago
Down 5% about 21 hours ago
Down 3% about 22 hours ago
Fell Below Previous Day's Low about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ocular Therapeutix, Inc. Description

Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Eye Inflammation Hypertension Clinical Trial Sealant Platform Technology Eye Diseases Glaucoma Cataracts Incision Allergic Conjunctivitis Treatment Of Glaucoma Cornea Allergology Cataract Surgery Incisions Ocular Hypertension Post Surgical Ocular Inflammation

Is OCUL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.31
52 Week Low 1.995
Average Volume 2,234,015
200-Day Moving Average 4.62
50-Day Moving Average 6.86
20-Day Moving Average 9.75
10-Day Moving Average 9.89
Average True Range 0.70
RSI (14) 59.51
ADX 51.14
+DI 24.52
-DI 20.15
Chandelier Exit (Long, 3 ATRs) 9.20
Chandelier Exit (Short, 3 ATRs) 8.48
Upper Bollinger Bands 11.54
Lower Bollinger Band 7.95
Percent B (%b) 0.41
BandWidth 36.79
MACD Line 0.77
MACD Signal Line 1.06
MACD Histogram -0.2873
Fundamentals Value
Market Cap 1.08 Billion
Num Shares 115 Million
EPS -1.01
Price-to-Earnings (P/E) Ratio -9.35
Price-to-Sales 11.86
Price-to-Book 83.06
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.45
Resistance 3 (R3) 10.40 10.01 10.28
Resistance 2 (R2) 10.01 9.76 10.04 10.22
Resistance 1 (R1) 9.73 9.60 9.54 9.78 10.17
Pivot Point 9.34 9.34 9.25 9.37 9.34
Support 1 (S1) 9.06 9.09 8.87 9.11 8.71
Support 2 (S2) 8.67 8.93 8.70 8.66
Support 3 (S3) 8.39 8.67 8.60
Support 4 (S4) 8.44